U.S., March 1 -- ClinicalTrials.gov registry received information related to the study (NCT06851806) titled 'Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease' on Feb. 10.
Brief Summary: This is a Phase IV, prospective, open-label, multicentre study to evaluate the safety of palivizumab IM injection for the prevention of severe LRTD in Indian infants and children who are at high-risk of RSV disease. All enrolled participants will receive palivizumab 15 mg/kg IM injection once a month for up to 5 injections during the study. Children who undergo cardiac surgery with cardiopulmonary bypass during the study should receive an additional dose of study intervention immediately after surgery, when...